Denileukin Diftitox (Lymphir) for Cutaneous T-Cell Lymphoma
Abstract
The FDA has approved the interleukin-2 (IL-2) receptor-directed fusion protein denileukin diftitox (Lymphir – Citius) for treatment of relapsed or refractory stage I-III cutaneous T-cell lymphoma in adults who received at least one prior systemic therapy. Lymphir is a reformulated, purified version of Ontak, which was voluntarily withdrawn from the market in 2014 because of manufacturing issues.
Fields of Study & Subjects
Cutaneous lymphoproliferative disorders research
Lymphoma Diagnosis and Treatment
Toxin Mechanisms and Immunotoxins
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Volume
- 68
- Issue
- 1748
- Pages
- e32–e33
- Publication date
- 6 February 2026
- Language
- EN